The Soltab Understanding Patient Preferences in ORal Therapy (SUPPORT) survey

• Conditions: depression; Mental Health - Depression

• Registration Number: ACTRN12607000310460
• Lead Sponsor: Adrenalin Strategics

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-06-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

Routine presentation of patients treated with conventional oral tablet mirtazapine- opportunistic assessment of patient suitabiltiy for participation in survey- identified patient categories likely to prefer orally disintegrating tablet formulation- after conducting risk-benefit analysis, patients who are likely to have a positive benefit are offered the opportunity to participate- patients must be agreeable to trial of mirtazapine orally disintegrating tablet formulation.

Exclusion Criteria

Patients not consenting to participation, or unable to provide valid consent- children aged < 18 years- depression not stabilised- duration of mirtazapine therapy < 3 months- known allergy or adverse effects to inactive ingredients in orally disintegrating formulation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of patient satisfaction with mirtazapine orally disintegrating formulation to that of mirtazapine conventional tablet formulation.[Satisfaction with conventional mirtazapine tablets is measured at baseline and comparison is made to satisfaction with mirtazapine orally disintegrating formulation at 1 month. A randomly selected group of patients is followed up at 6 months.]

Secondary Outcome Measures

Name	Time	Method
Identification of factors that patients consider a priority in choosing their antidepressant therapy.<br>[Attitudes regarding priorities in antidepressant choice are examined at baseline. Comparison is made at one month. A randomly selected group of patients will be surveyed at 6 months.];Whether patients' perception of control over their therapeutic decisions influences their likelihood of medication adherance.<br>[Patients perceptions of level of control and self-reports of treatment adherance are measured at baseline. Comparison made at 1 month. Randomly selected group of patients followed up at 6 months.]